JP2016510213A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510213A5
JP2016510213A5 JP2015551852A JP2015551852A JP2016510213A5 JP 2016510213 A5 JP2016510213 A5 JP 2016510213A5 JP 2015551852 A JP2015551852 A JP 2015551852A JP 2015551852 A JP2015551852 A JP 2015551852A JP 2016510213 A5 JP2016510213 A5 JP 2016510213A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
iro compound
composition according
iro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015551852A
Other languages
English (en)
Japanese (ja)
Other versions
JP6385957B2 (ja
JP2016510213A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/010599 external-priority patent/WO2014110081A1/en
Publication of JP2016510213A publication Critical patent/JP2016510213A/ja
Publication of JP2016510213A5 publication Critical patent/JP2016510213A5/ja
Application granted granted Critical
Publication of JP6385957B2 publication Critical patent/JP6385957B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015551852A 2013-01-08 2014-01-08 トール様受容体に基づく免疫応答を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物 Expired - Fee Related JP6385957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750014P 2013-01-08 2013-01-08
US61/750,014 2013-01-08
PCT/US2014/010599 WO2014110081A1 (en) 2013-01-08 2014-01-08 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

Publications (3)

Publication Number Publication Date
JP2016510213A JP2016510213A (ja) 2016-04-07
JP2016510213A5 true JP2016510213A5 (enExample) 2016-12-28
JP6385957B2 JP6385957B2 (ja) 2018-09-05

Family

ID=51061112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015551852A Expired - Fee Related JP6385957B2 (ja) 2013-01-08 2014-01-08 トール様受容体に基づく免疫応答を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物

Country Status (9)

Country Link
US (3) US9260719B2 (enExample)
EP (1) EP2943251B1 (enExample)
JP (1) JP6385957B2 (enExample)
KR (1) KR101898177B1 (enExample)
AU (2) AU2014205544B2 (enExample)
BR (1) BR112015016420B1 (enExample)
CA (1) CA2896537C (enExample)
HK (1) HK1214191A1 (enExample)
WO (1) WO2014110081A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101898177B1 (ko) * 2013-01-08 2018-09-12 이데라 파마슈티칼즈, 인코포레이티드 톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물
WO2016130832A1 (en) 2015-02-13 2016-08-18 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
US20190046638A1 (en) 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
CA3044484A1 (en) * 2016-11-23 2018-05-31 Berlin Cures GmbH Aptamers for use in inhibition and/or suppression of tlr9 activation
AU2018364542A1 (en) 2017-11-08 2020-04-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
SG11202009647VA (en) 2018-04-09 2020-10-29 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
ATE384072T1 (de) * 2000-09-26 2008-02-15 Idera Pharmaceuticals Inc Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
US7105495B2 (en) * 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en) * 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
AU2004206820B2 (en) * 2003-01-16 2010-06-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
EE200700003A (et) * 2004-06-15 2007-06-15 Idera Pharmaceuticals, Inc. Immunostimuleeriv oligonukleotiid ning selle kasutamine
US8426375B2 (en) 2005-10-12 2013-04-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8399423B2 (en) 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8383598B2 (en) 2005-10-12 2013-02-26 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CN101287742B (zh) * 2005-10-12 2016-01-06 艾德拉药物股份有限公司 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
US7776834B2 (en) * 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7709317B2 (en) * 2005-11-14 2010-05-04 International Business Machines Corporation Method to increase strain enhancement with spacerless FET and dual liner process
MX2008008279A (es) * 2005-12-20 2009-03-04 Idera Pharmaceuticals Inc Actividad inmunoestimuladora de oligonucleotidos inmunoestimuladores palindromicos que contienen diferentes longitudes de segmentos palindromicos.
CN101460178B (zh) * 2006-04-07 2016-12-07 艾德拉药物股份有限公司 用于tlr7和tlr8的稳定化的免疫调节性rna(simra)化合物
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
AU2007333146A1 (en) * 2006-12-12 2008-06-19 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR9
US8713253B1 (en) * 2007-06-18 2014-04-29 Guidance-Tableau, Llc Modular storage system
EP2357231A2 (en) * 2007-07-09 2011-08-17 Idera Pharmaceuticals, Inc. Stabilized immune modulatory RNA (SIMRA) compounds
ES2539353T3 (es) * 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Nuevos agonistas sintéticos de TLR9
MX2010001785A (es) * 2007-08-15 2010-03-10 Idera Pharmaceuticals Inc Moduladores de receptores tipo larga distancia.
WO2009154609A1 (en) * 2008-06-17 2009-12-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
CN102281880A (zh) 2008-10-06 2011-12-14 艾德拉药物股份有限公司 类Toll受体抑制剂在高胆固醇血症和高脂血症及相关疾病的预防和治疗中的用途
CA2762206C (en) * 2009-06-01 2017-06-27 Idera Pharmaceuticals, Inc. Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9
US9415046B2 (en) 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
MX338980B (es) 2010-06-16 2016-05-06 Dynavax Tech Corp Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
JP5813778B2 (ja) * 2010-11-19 2015-11-17 イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物
RU2606114C2 (ru) * 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы
US20140378537A1 (en) * 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
WO2013155487A1 (en) * 2012-04-12 2013-10-17 Yale University Vehicles for controlled delivery of different pharmaceutical agents
KR101898177B1 (ko) * 2013-01-08 2018-09-12 이데라 파마슈티칼즈, 인코포레이티드 톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물
EP3681125A1 (en) * 2013-05-30 2020-07-15 Intel Corporation Adaptive authentication systems and methods
WO2016130832A1 (en) * 2015-02-13 2016-08-18 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2013544816A5 (enExample)
Velkov et al. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead
ES2967453T3 (es) Compuestos de pirrolizina sustituidos y usos de los mismos
JP2010536787A5 (enExample)
Gane Future anti‐HBV strategies
JP2015517489A5 (enExample)
JP2006524669A5 (enExample)
JP2018520646A5 (enExample)
PH12017500797A1 (en) Substituted chromanes and methods of use
JP2020508310A5 (enExample)
ES2897599T3 (es) Mejora de la administración de genes a células asesinas naturales, células madre hematopoyéticas y macrófagos
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
JP2017526728A5 (enExample)
JP2017531002A5 (enExample)
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
JP2015528447A5 (enExample)
JP2011528332A5 (enExample)
Zhang et al. The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo
JP2015505843A5 (enExample)
EA202090465A1 (ru) Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк- и/или днк-содержащими вирусами, и сопутствующих заболеваний
JP2019506862A5 (enExample)
JP2019531293A5 (enExample)
JP2016517446A5 (enExample)
JP2018509380A5 (enExample)
MX2022003590A (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9.